Table 4.
Clinical applications of the developed MS BA model.
| Age group | Normal | Risk | Metabolic syndrome | P value | |||
|---|---|---|---|---|---|---|---|
| N (%) | Mean ± SD | N (%) | Mean ± SD | N (%) | Mean ± SD | ||
| Male | |||||||
| TG (n = 8,671,838) | 2,002,914 (100) | –12.64 ± 8.86 | 4,872,818 (100) | –0.78 ± 10.78 | 1,796,106 (100) | 16.23 ± 10.11 | < .0001 |
| YG (n = 2,463,455) | 823,782 (41.1) | –11.76 ± 8.66 | 1,287,877 (26.4) | 0.94 ± 10.88 | 351,796 (19.6) | 19.18 ± 9.97 | < .0001 |
| MG (n = 4,118,565) | 857,424 (42.8) | –12.65 ± 8.83 | 2,338,587 (48.0) | –0.40 ± 10.73 | 922,554 (51.4) | 16.45 ± 10.07 | < .0001 |
| OG (n = 2,089,818) | 321,708 (16.1) | –14.84 ± 9.05 | 1,246,354 (25.6) | –3.28 ± 10.33 | 521,756 (29) | 13.84 ± 9.68 | < .0001 |
| Female | |||||||
| TG (n = 7,846,694) | 2,677,507 (100) | –9.06 ± 8.07 | 3,889,567 (100) | 0.77 ± 9.71 | 1,279,620 (100) | 16.5 ± 10.56 | < .0001 |
| YG (n = 1,376,061) | 840,140 (31.4) | –5.50 ± 7.47 | 480,365 (12.4) | 6.64 ± 9.62 | 55,556 (4.3) | 27.64 ± 9.94 | < .0001 |
| MG (n = 4,022,863) | 1,480,041 (55.3) | –9.85 ± 7.58 | 2,042,509 (52.5) | 1.71 ± 9.26 | 500,313 (39.1) | 19.57 ± 9.82 | < .0001 |
| OG (n = 2,447,770) | 357,326 (13.3) | –14.18 ± 7.72 | 1,366,693 (35.1) | –2.70 ± 9.05 | 723,751 (56.6) | 13.53 ± 9.90 | < .0001 |
Young group: 20.0 ≤ Age < 40.0 years, Middle group: 40.0 ≤ Age < 60.0 years, Old group: Age ≥ 60.0 years.
TG total group, YG young group, MG middle group, OG old group, SD standard deviation.